My Science & Publications

Select Dietary and Metabolic Health-Related Publications


  1. Kelly DL, Glassman M, Wonodi I, Vyas G, Richardson CM, Nwulia E, Wehring HJ, Oduguwa T, Mackowick M, Hipolito MMS, Peters O, Rai N, Park J, Adebayo AO, Gorelick DA, Weiner E, Liu F, Kearns AM, Adams HA, Love RC, Chen S, Olaniyan A, Ambulos N, McKoy D, Nallani MC, Lanzkron S, Mengistab M, Barr B, Davis E, Lawal R, Buchanan RW, Adebayo R. Clozapine and neutrophil response in patients of African descent: A six-month, multinational, prospective, open-label clinical trial. Schizophr Res. 2023 Aug 24:S0920-9964(23)00260-8. doi: 10.1016/j.schres.2023.08.002. Epub ahead of print. PMID: 37633776.

  2. Shukla RP, Rapiera C, Glassman M, Liu F, Kelly DL, Ben-Yoav, Hadar. An integrated electrochemical microsystem for real-time treatment monitoring of clozapine in microliter volume samples from schizophrenia patients. Electrochemistry Communications, Oct 2020 doi.org/10.1016/j.elecom.2020.106850

  3. Siskind D, Honer WG, Clark S, Correll CU, Hasan A, Howes O, Kane JM, Kelly DL, Laitman R, Lee J, MacCabe JH, Myles N, Nielsen J, Schulte PF, Taylor D, Verdoux H, Wheeler A, Freudenreich O. Clozapine and COVID-19: The authors respond. J Psychiatry Neurosci. 2020 Jul 1;45(4):E1-E2. doi: 10.1503/jpn.2045302.PMID: 32584530

  4. Zarzar TR, Kelly DL. Clozapine for Self-Injurious and Aggressive Behaviors in Correctional Settings. Journal of International Corrections and Prisons Association, (Advancing Corrections), Edition #12-2021 pgs 108-117.

  5. de Leon J, Schoretsanitis G, Smith RL, Molden E, Solismaa A, Seppälä N, Kopeček M, Švancer P, Olmos I, Ricciardi C, Iglesias-Garcia C, Iglesias-Alonso A, Spina E, Ruan CJ, Wang CY, Wang G, Tang YL, Lin SK, Lane HY, Kim YS, Kim SH, Rajkumar AP, González-Esquivel DF, Jung-Cook H, Baptista T, Rohde C, Nielsen J, Verdoux H, Quiles C, Sanz EJ, De Las Cuevas C, Cohen D, Schulte PFJ, Ertuğrul A, Anıl Yağcıoğlu AE, Chopra N, McCollum B, Shelton C, Cotes RO, Kaithi AR, Kane JM, Farooq S, Ng CH, Bilbily J, Hiemke C, López-Jaramillo C, McGrane I, Lana F, Eap CB, Arrojo-Romero M, Rădulescu FŞ, Seifritz E, Every-Palmer S, Bousman CA, Bebawi E, Bhattacharya R, Kelly DL, Otsuka Y, Lazary J, Torres R, Yecora A, Motuca M, Chan SKW, Zolezzi M, Ouanes S, De Berardis D, Grover S, Procyshyn RM, Adebayo RA, Kirilochev OO, Soloviev A, Fountoulakis KN, Wilkowska A, Cubała WJ, Ayub M, Silva A, Bonelli RM, Villagrán-Moreno JM, Crespo-Facorro B, Temmingh H, Decloedt E, Pedro MR, Takeuchi H, Tsukahara M, Gründer G, Sagud M, Celofiga A, Ignjatovic Ristic D, Ortiz BB, Elkis H, Pacheco Palha AJ, LLerena A, Fernandez-Egea E, Siskind D, Weizman A, Masmoudi R, Mohd Saffian S, Leung JG, Buckley PF, Marder SR, Citrome L, Freudenreich O, Correll CU, Müller DJ. An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. Pharmacopsychiatry. 2022 Mar;55(2):73-86. doi: 10.1055/a-1625-6388. Epub 2021 Dec 15. PMID: 34911124

  6. Buckley T, Kitchen C, Vyas G, Siegfried NA, Tefera E, Chen S, DiPaula BA, Kelly DL. Comparison of Novel Immunoassay With Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS) for Therapeutic Drug Monitoring of Clozapine. Ther Drug Monit, 2020 Oct; 42 (5):771-777. PMID 32569062

  7. Kelly DL, Ponomareva OY, Mackowick M, Glassman M, Park J, Navarro-De La Vega M, Wehring HJ, Vyas G. Feasibility and patient-reported satisfaction using a novel point-of-care fingerstick method for monitoring absolute neutrophil count for clozapine. Ann Clin Psychiatry, 2021 May;33 (2):116-123. PMID 33878286

  8. Siskind D, Honer WG, Clark S, Correll CU, Hasan A, Howes O, Kane JM, Kelly DL, Laitman R, Lee J, MacCabe JH, Myles N, Nielsen J, Schulte PF, Taylor D, Verdoux H, Wheeler A, Freudenreich O. Consensus statement on the use of clozapine during the COVID-19 pandemic. J Psychiatry Neurosci. 2020 Apr 3;45(4):200061. doi: 10.1503/jpn.200061. PMID: 32242646.

  9. Kalaria SN, Kelly DL. Development of point-of-care testing devices to improve clozapine prescribing habits and patient outcomes. Neuropsychiatr Dis Treat. 2019 Aug 20;15:2365-2370. doi: 10.2147/NDT.S216803. PMID: 31692521 PMCID: PMC6708436

  10. Shukla RP, Cazelles R, Kelly DL, Ben-Yoav H. A reduced-graphene oxide-modified microelectrode for a repeatable detection of antipsychotic clozapine using microliters-volumes of whole blood. Talanta. 2020 Mar 1; 209:120560. doi: 10.1016/j.talanta.2019.120560. PMID: 31892051

  11. Davis EAK, Kelly DL. Clozapine-associated renal failure: A case report and literature review. Ment Health Clin. 2019 May 10;9(3):124-127. doi: 10.9740/mhc.2019.05.124. PMID: 31123659 PMCID: PMC6513053

  12. Stolz PA, Wehring HJ, Liu F, Love RC, Ellis M, DiPaula BA, Kelly DL. Effects of Cigarette Smoking and Clozapine Treatment on 20-Year All-Cause & Cardiovascular Mortality in Schizophrenia. Psychiatr Q. 2019 Jan 10. doi: 10.1007/s11126-018-9621-4. [Epub ahead of print] PMID: 30632082 PMCID: PMC6525042

  13. Kelly DL, Love RC. Psychiatric pharmacist's role in overcoming barriers to clozapine use and improving management.  Ment Health Clin. 2019 Mar 1;9(2):64-69. doi: 10.9740/mhc.2019.03.064. eCollection 2019 Mar. PMID: 30842912 PMCID: PMC6398355

  14. Stolz PA, Wehring HJ, Liu F, Love RC, Ellis M, DiPaula BA, Kelly DL. Effects of Cigarette Smoking and Clozapine Treatment on 20-Year All-Cause & Cardiovascular Mortality in Schizophrenia.  Psychiatr Q. 2019 Jun;90(2):351-359. doi: 10.1007/s11126-018-9621-4. PMID: 30632082 PMCID: PMC6525042

  15. Treatment monitoring in schizophrenia. The role of microsystems integration towards point-of-care clozapine. IEEE Sens Lett. 2018;1: pii: 5500304. Dec 13. PMID: 29308452 PMCID: PMC5754032

  16. Kelly DL*, Ben-Yoav H*, Payne GF, Winkler TE, Chocron SE, Kim E, Stock V, Vyas G, Love RC, Wehring HJ, Sullivan KM, Feldman SF, Liu F, McMahon RP, Ghodssi R.  Blood draw barriers for treatment with clozapine and development of point-of-care monitoring device. Clinical Schizophrenia & Related Disorders, 2018;12:23-30 PMID: 26218235 DOI: 10.3371/CSRP.KEBE.070415

  17. Temocin Z, Kim E, Li J, Panzella L, Alfierei ML, Japolitano A, Kelly DL, Bently WE, Payne GF. The analgesic acetaminophen and antipsychotic clozapine can each redox-cycle with melanin. ACS Chem Neuroscien 2017;8(12);2766-2777. PMID 28945963

  18. Patchan K, Vyas G, Hackman AL, Mackowick M, Richardson CM, Love RC, Wonodi I, Sayer MA, Glassman M, Feldman S, Kelly DL.  Clozapine in reducing aggression and violence in forensic populations. Psych Quarterly 2018;89(1):157-168.  PMID: 28643049 PMCID: PMC5930356

  19. Wehring HJ, Elsobky T, McEvoy JP, Vyas G, Richardson CM, McMahon RP, DiPaula BA, Liu F, Sullivan K, Buchanan RW, Feldman S, McMahon RP, Kelly DL. Adjunctive minocycline in clozapine-treated patients with schizophrenia: analyzing the effects of minocycline on clozapine plasma levels. Psych Quarterly 2018;89(1):73-80. PMID: 28466366 PMCID: PMC5670021

  20. Kelly DL, Freudenreich O, Sayer MA, Love RC. Addressing barriers to clozapine underutilization: a national effort. Psychiatr Serv 2018;69:224-227. PMID  29032704Kang M, Kim E, Winkler TE, Banis G, Liu Y, Kitchen CA, Kelly DL, Ghodssi R, Payne GF.  Reliable clinical serum analysis with reusable electrochemical sersor:  Toward point-of-care measurement of the antipsychotic medication clozapine.  Biosens Bioelectron.  2017;;95:55-59.  PMID: 28412661 PMCID: PMC5523846

  21. Winkler TE, Lederer SL, Kim E, Ben-Yoav H, Kelly DL, Payne GF, Ghodssi R.  Molecular processes in an electrochemical clozapine sensor. Biointerphases. 2017 May 1;12(2):02B401. doi: 10.1116/1.4982709. PMID: 28460529 PMCID: PMC5552401

  22. Winkler TE, Dietrich R, Kim E, Ben-Yoav H, Kelly DL, Payne GF, Ghodssi R. The interplay of electrode- and bio-materials in a redox-cycling-based clozapine sensor. Electrochem commun. 2017 Jun;79:33-36. doi: 10.1016/j.elecom.2017.04.009. Epub 2017 Apr 13. PMID: 28729810 PMCID: PMC5512729

  23. Norman SM, Sullivan KM, Liu F, DiPaula BA, Jose PA, Kitchen CA, Feldman SM, Kelly DL. Blood pressure and heart rate changes during clozapine treatment. Psychiatr Quarterly 2017;88(3):545-552. PMID: 27678498 PMCID: PMC5484721

  24. Banis GE, Winkler TE, Barton P, Chocron SE, Kim E, Kelly DL, Payne GF, Ben-Yoav H, Ghodssi R. The binding effects of proteins on medications and its impact on electrochemical sensing: antipsychotic clozapine as a case study.  Pharmaceuticals. 2017;10: pii: E69. doi: Legge SE, Hamshere ML, Ripke S, Pardinas AF, Goldstein JI, Rees E, Riahcards AL, Leonenko G, Jarskog LF, Clozapine-Induced Agranulocytosis Consortium. Genome-wide common and rare variant analysis provides novel insights into clozapine-associated Neutropenia. Mol Psychiatry 2016 epub ahead of print  PMID: 27400856 PMCID: PMC5065090

  25. Richardson CM*, Davis EA,* Vyas GR, DiPaula BA, McMahon RP, Kelly DL. Evaluation of the safety of clozapine use in patients with benign neutropenia.  J Clin Psych 2016;77(11):e1454-e1459.  PMID: 27736047 PMCID: PMC5470316

  26. Kelly, DL, Sullivan KM, McEvoy JP, McMahon RP, Wehring HJ, Liu F, Warfel D, Vyas G, Richardson CM, Fischer BA, Keller WR, Koola MM, Feldman, SM, Russ JC, Keefe RS, Osing J, Hubzin L, August A, Walker TM, Buchanan RW.  Adjunctive Minocycline in clozapine treated schizophrenia patients with persistent symptoms. J Clin Psychopharmacol. 2015 Aug;35(4):374-81. doi: 10.1097/JCP.0000000000000345. PMID: 26082974 PMCID: PMC4485552

  27. Patchan KM, Richardson C, Vyas G, Kelly DL.  The risk of suicide after clozapine discontinuation: cause for concern.  Ann Clin Psychiatry, 2015 Nov; 27(4):253-256.  PMID: 26554366 PMCID: PMC5470314 

  28. Ben-Yoav H, Chocron SE, Winkler TE, Kim E, Kelly DL, Payne GF, Ghodssi R.  An electrochemical micro-system for clozapine antipsychotic treatment monitoring.  2015;163:260-270.

  29. Ben-Yoav H, Winkler TE, Kim E, Chocron SE, Kelly DL, Payne GF, Ghodssi R.  Redox cycling- based amplifying electrochemical sensor for in situ clozapine antipsychotic treatment monitoring. Electrochimica Actra 2014;130:497-503.

  30. Kelly DL, Wehring HJ, Vyas G. Current status of clozapine in the US. Shanghai Arch of Psychiatry, 2012;24:110-113. PMID: 25324612 PMCID: PMC4198838

  31. Kelly DL, Vyas G, Richardson CM, Koola MM, McMahon RP, Buchanan RW, Wehring HJ. Adjunct Minocycline to Clozapine in Treatment Resistant Schizophrenia. Schizophrenia Research. 2011;13:257-8. PMID: 21872445

  32. Winkler T, Ben-Yoav H, Chocron S, Kim E, Kelly DL, Payne G, Ghodssi R. Electrochemical Study of the Catechol-modified Chitosan System for Clozapine Treatment Monitoring. Langmuir 2014;30:14686-93. PMID: 25383917

  33. Goldstein JI, Fredrik Jarskog L, Hilliard C, Alfirevic A, Duncan L, Fourches D, Huang H, Lek M, Neale BM, Ripke S, Shianna K, Szatkiewicz JP, Tropsha A, van den Oord EJ, Cascorbi I, Dettling M, Gazit E, Goff DC, Holden AL, Kelly DL, Malhotra AK, Nielsen J, Pirmohamed M, Rujescu D, Werge T, Levy DL, Josiassen RC, Kennedy JL, Lieberman JA, Daly MJ, Sullivan PF. Clozapine –induced agranulocytosis is associated with rare HLA-DQB1 and HLA alleles. Nat Commun 2014;5:4757. PMID: 25187353 PMCID: PMC4155508

  34. Kelly DL, McMahon RP, Liu F, Love RC, Wehring HJ, Shim JC, Warren KR, Conley RR. Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study. J Clin Psychiatry. 2010;71:304-11. PMID: 20079332 PMCID: PMC3607426

  35. Kelly DL, Feldman S, Boggs DL, Gale E, Richardson CM, Conley RR. Nonresponse to clozapine and premorbid functioning in treatment of refractory schizophrenia. Comprehensive Psychiatry. 2010;51;298-302. PMID 20399340

  36. Weiner E, Conley RR, Ball MP, Feldman S, Gold JM, Kelly DL, Wonodi I, McMahon RP, Buchanan RW. Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine Neuropsychopharmacology. 2010;35;2274-83. PMID: 20664583 PMCID: PMC2939921

  37. Kelly DL, Linthicum J, Wehring HJ, Feldman S, McMahon RP, Lover RC, Wagner T, Shim J-C, Fowler DR. Cardiac-Related findings at autopsy in people with severe mental illness treated with clozapine or risperidone. Schizophrenia Research. 2009;107:134-8. PMID:19028422 PMCID: PMC3742085

  38. Boggs DL, Kelly DL, Love RC, McMahon RP, Conley RR. Comparison of Clozapine Response for Inpatients in the Research Setting versus Routine Clinical Practice. Psychiatric Quarterly. 2008;79(2):111-119. PMID:18214677 PMCID: PMC4120101

  39. Kelly DL, Kreyenbuhl J, Buchanan RW, Malhotra MK. Why Not Clozapine? Clinical Schizophrenia & Related Psychoses. 2007;1:92-5.

  40. Kelly DL, Kreyenbuhl J, Dixon L, Love RC, Medoff D, Conley RR. Clozapine Underutilization and Discontinuation in African-Americans Due to Leukopenia. Schizophrenia Bulletin. 2007;33(5):1221-4. PMID:17170061 PMCID: PMC2632351

  41. Kelly DL, Conley RR, Feldman S, Yu Y, McMahon RP, Richardson CM. Adjunct Divalproex or Lithium to Clozapine in Treatment-Resistant Schizophrenia. Psychiatric Quarterly. 2006;77(1):81-95. PMID:16397757 

  42. Kelly DL, Dixon L, Kreyenbuhl J, Lehman AF, Love RC, Medoff D, Brown C, Conley RR. Clozapine Utilization and Outcomes by Race in a Public Mental Health System: 1994-2000. J Clin Psychiatry. 2006;67:1404-11. PMID:17017827

  43. Conley RR, Kelly DL, Beason-Held, Holcomb H, Richardson C, Tamminga CA, Carpenter WT. The effects of clozapine and high dose olanzapine on brain function in treatment-resistant schizophrenia: a case study. Journal of Psychopharmacology. 2004;18:429-31. PMID:15358989

  44. Conley RR, Kelly DL, Lambert TJ, Love RC. A comparison of clozapine use in Maryland and in Victoria, Australia. Psychiatric Services. 2005;56:320-3. PMID:15746507

  45. Kelly DL, Gale EA, Yu Y, Conley RR. Clozapine treatment in patients with prior substance abuse. Canadian Journal of Psychiatry. 2003;48(2):111-4. 

  46. Wehring H, Kelly DL, Love RC, Conley RR. Deaths from diabetic ketoacidosis after long-term clozapine treatment. Am J Psychiatry. 2003;160:2241-2242. PMID:14638600.

  47. Conley RR, Kelly DL, Richardson CM, Tamminga CA, Carpenter WT Jr.  The Efficacy of High Dose Olanzapine vs. Clozapine in Treatment-Resistant Schizophrenia: A Double-Blind Crossover Study.  J Clin Psychopharmacology. 2003;23:668-671. PMID: 14624201.

  48. Conley RR, Love RC, Kelly DL, Bartko JJ.  Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine. American Journal of Psychiatry. 1999;156:863-868. PMID:10360124.

  49. Conley RR, Tamminga CA, Kelly DL, Richardson C. Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response.  Biological Psychiatry. 1999; 46;73-77. PMID:10394475.


Select Clozapine-Related Publications

Books and Book Chapters


  1. Conley RR, Kelly DL. Pharmacologic treatment of schizophrenia. Professional Communications, Inc. First Edition, Caddo, OK 2000.

  2. Conley RR, Kelly DL. Pharmacologic treatment of schizophrenia.  Professional Communications, Inc. Second Edition, Caddo, OK 2003.

  3. Conley RR, Kelly DL. Pharmacologic treatment of schizophrenia.  Professional Communications, Inc. Third Edition, Caddo, OK, 2007.

  4. Conley RR, Kelly DL. The long-term efficacy, effectiveness and safety of second-generation antipsychotic drugs. In: Atypical antipsychotics: from bench to bedside. Editors: Csernansky JG, Lauriello J.  Marcel Dekker 2004.

  5. Conley RR, Kelly DL. Schizophrenia.  In Conn’s Current Therapy 2005.  Editors:  Rakel R and Bope E. Philadelphia, PA: W.B. Saunders, Philadelphia 2005, pp. 1280-1284. 

  6. Conley RR, Kelly DL. Schizophrenia. In Conn’s Current Therapy 2006. Editors: Rakel R and Bope E. Philadelphia, PA:  W. B. Saunders, Philadelphia 2006, 1370-1374.

  7. Boggs D, Kelly DL, Conley RR. Antipsychotic Therapeutics (Efficacy and Side Effects). In The Year in Schizophrenia Volume I. Editors: Thaker G, Carpenter WT., Clinical Publishing, Oxford, UK.  2007,209-231.

  8. Kelly DL, Weiner E. Schizophrenia, in Pharmacotherapy Principles and Practice, Chisholm-Burns M, Wells BG, Schwinghammer TL, et al (eds), McGraw-Hill, New York, New York, 2008.

  9. Kelly DL, Boggs DL, Conley RR. Reaching for wellness in schizophrenia:  A Complex Disease Necessitating Complex Care. Psychiatric Clinics of North America, Buckley PF, Messias EL (eds), Saunders, Philadelphia, PA 2007;30:453-479.

  10. Boggs D, Kelly DL. Antipsychotic Therapeutics. In The Year in Schizophrenia Volume II. Editors: Thaker G, Carpenter WT., Clinical Publishing, Oxford, UK.  2008.

  11. Wehring HJ, Kelly DL. Sexual Dysfunction in Schizophrenia. In: Medical Illness in Schizophrenia, second edition 2009. Eds Meyer JM, Nasrallah HA. American Psychiatric Publishing, Inc.

  12. Kelly DL, Weiner E, Wehring H. Schizophrenia, in Pharmacotherapy Principles and Practice, second edition. Chisholm-Burns M, Wells BG, Schwinghammer TL, et al (eds), McGraw-Hill, New York, New York, 2010.

  13. Perez G, Dixon L, Kelly DL. Evidence Based Medicine. In: Levin BL, Becker MA (Eds.). A Public Health Perspective of Women's Mental Health. New York: Springer, 2010. https://books.google.com/books?id=RCjJT9WuaokC&pg=PR18&lpg=PR18&dq=deanna+kelly+pharmd&source=bl&ots=Xwb7PZM2Wt&sig=Gmv9cuwGDzC7iZHH3N0GtcoA_1c&hl=en&sa=X&ved=0ahUKEwjc5fvb7pnbAhWMt1kKHdb0AyI4FBDoAQguMAE#v=onepage&q=deanna%20kelly%20pharmd&f=false

  14. Kelly DL, Buchanan RW. Clozapine: It’s Current Status In and Beyond Treatment Resistant Schizophrenia. In: Therapeutic Strategies in Schizophrenia. 2010. Eds., P McKenna, A. Mortimer. Clinical Publishing Limited.

  15. Wehring HJ, Kelly DL. Schizophrenia. In; Pharmacotherapy Principles & Practice Study Guide: A Cased Based Care Plan Approach, First Edition.  Michael D. Katz, Kathryn R. Matthias, and Marie A. Chisholm-Burns, Editors. The McGraw-Hill Companies, Inc. 2010.

  16. Kelly DL, Weiner E, Wehring H. Schizophrenia, in Pharmacotherapy Principles and Practice, third edition, Chrisholm, Burns M, Wells BG, Schwinghammer TL, et al (eds), McGraw-Hill, New York, New York, 2012 

  17. Kelly DL, Weiner E, Wehring H. Schizophrenia, in Pharmacotherapy Principles and Practice, third edition, Chrisholm, Burns M, Wells BG, Schwinghammer TL, et al (eds), McGraw-Hill, New York, New York, 2014 

  18. Kelly DL, Weiner E, Wehring H. Schizophrenia, in Pharmacotherapy Principles and Practice, fourth edition, Chrisholm, Burns M, Wells BG, Schwinghammer TL, et al (eds), McGraw-Hill, New York, New York, 2016.

  19. Kelly DL, Weiner E, Wehring H. Schizophrenia, in Pharmacotherapy Principles and Practice, fourth edition, Chrisholm, Burns M, Wells BG, Schwinghammer TL, et al (eds), McGraw-Hill, New York, New York, 2018 

  20. Kelly DL, Borovicka M. Schizophrenia, in Pharmacotherapy Principles and Practice, fourth edition, Chrisholm, Burns M, Wells BG, Schwinghammer TL, et al (eds), McGraw-Hill, New York, New York, 2020

  21. Kelly DL, Borovicka M. Schizophrenia, in Pharmacotherapy Principles and Practice, fourth edition, Chrisholm, Burns M, Wells BG, Schwinghammer TL, et al (eds), McGraw-Hill, New York, New York, 2022

  22. Kelly DL, Borovicka M. Schizophrenia, in Pharmacotherapy Principles and Practice, fourth edition, Chrisholm, Burns M, Wells BG, Schwinghammer TL, et al (eds), McGraw-Hill, New York, New York, 2024




  1. Kelly DL, Lee CM, Roche DJO, Talor MV, Clark S, Eaton WW. Randomized Double Blind Inpatient Study of a Gluten-Free Diet in Persons with Schizophrenia. med Rxiv [Preprint]. 2025 Feb 25:2025.02.24.25322813. doi: 10.1101/2025.02.24.25322813. PMID: 40061327; PMCID: PMC11888518.

  2. Buchanan RW, Werkheiser AE, Michel H, Zaranski J, Glassman M, Adams HA, Vyas G, Blatt F, Pilli NR, Pan Y, Chen S, Fraser CM, Kelly DL, Kane MA. Prebiotic Treatment in People With Schizophrenia. J Clin Psychopharmacol. 2024 Sep-Oct 01;44(5):457-461. doi: 10.1097/JCP.0000000000001899. Epub 2024 Aug 16. PMID: 39146178; PMCID: PMC11384470.

  3. Kim E, Redwood S, Liu F, Roche D, Chen S, Bentley WE, Eaton WW, Cihakova D, Talor MV, Kelly DL, Payne GF. Pilot study indicates that a gluten-free diet lowers oxidative stress for gluten-sensitive persons with schizophrenia. Schizophrenia Research 2024 July; 269: 71-78. Doi: 10.1016/j.schres.2024.05.001

  4. Kulaga SS, Kelly DL. Nutrition in the Treatment of Schizophrenia: Rationale and Review of Recent Evidence. Curr Behav Neurosci Rep  2023;10:49–57. doi.org/10.1007/s40473-023-00259-2

  5. Daniels EC, Eaton WW, Cihakova D, Talor MV , Lemke H , Mo C , Chen  S, Notarangelo FM , Rodriguez KM , and Kelly DL. The relationship of peripheral inflammation with antibodies to gliadin (AGA IgG) in persons with schizophrenia. Schizophrenia Research; 2023;256:50-51. doi.org/10.1016/j.schres.2023.02.027

  6. Nallani MC, Powell MM., Pugh S, Kearns AM, Adams HA., Weiner E, Wehring HJ., McEvoy JP., Buckley PF., Liu F, Buchanan RW., Kelly DL. 25-Hydroxyvitamin D and metabolic-related laboratory values in women with schizophrenia and hyperprolactinemia. J Psychiatr Res . 2022 Apr 8;151:25-29. doi: 10.1016/j.jpsychires.2022.03.046. PMID: 35429802

  7. Friendshuh CR, Pocivavsek A, Demyonovich H, Rodriguez KM, Cihakova D, Talor MV, Richardson CM, Vyas G, Adams HA, Baratta AB, Fasano A, Cascella N, Feldman S, Liu F, Sayer M, Powell MM, Wehring HJ, Buchanan RW, Carpenter Jr WT, Eaton WW, Kelly DL. The Effects of a Gluten-Free Diet on Immune Markers and Kynurenic Acid Pathway Metabolites in Patients With Schizophrenia Positive for Antigliadin Antibodies Immunoglobulin G. J Clin Psychopharmacol . May/Jun 2020;40(3):317-319. doi: 10.1097/JCP.0000000000001197. PMID: 32332475 PMCID: PMC7185031

  8. Kelly DL, Demyanovich HK, Rodriguez KM, Ciháková D, Talor MV, McMahon RP, Richardson CM, Vyas G, Adams HA, August SM, Fasano A, Cascella NG, Feldman SM, Liu F, Sayer MA, Powell MM, Wehring HJ, Buchanan RW, Gold JM, Carpenter WT, Eaton WW. Randomized controlled trial of a gluten-free diet in patients with schizophrenia positive for antigliadin antibodies (AGA IgG): a pilot feasibility study. J Psychiatry Neurosci. 2019 Jul 1;44(4):269-276. PMID: 30938127 PMCID: PMC6606425

  9. Cihakova D, Eaton WW, Talor MV, Harkus UH, Demyanovich H, Rodriguez K, Feldman S, Kelly DL. Gut permeability and mimicry of the Glutamate Ionotropic Receptor NMDA type Subunit Associated with protein 1 (GRINA) as potential mechanisms related to a subgroup of people with schizophrenia with elevated antigliadin antibodies (AGA IgG). Schizophr Res 2019 Jun;208:414-419. doi: 10.1016/j.schres.2019.01.007. Epub 2019 Jan 24 PMID: 30685393

  10. Cihakova D, Eaton WW, Talor MV, Harkus UH, Demyanovich H, Rodriguez K, Feldman S, Kelly DL.   Gliadin-related antibodies in schizophrenia. Schizophrenia Research, 2018;195;585-586 PMID: 28886891

  11. Kelly DL, Demyanovich HK, Eaton W, Cascella N, Jackson J, Fasano A, Carpenter WT. Antigliadin antibodies (AGA IgG) related to peripheral inflammation in schizophrenia. Brain Behav Immun 2018;69:57-59. PMID  29074356

  12. Rowland LM, Demyanovich HA, Witjenberg SA, Eaton WW, Rodriguez K, Gaston F, Cihakova D, Talor MV, Liu F, McMahon RP, Hong LE, Kelly DL.  Antigliadin antibodies (AGA IgG) are related to neurochemistry in schizophrenia. Frontiers in Psychiatry 2017:8:104  PMID 28674504 PMCID: PMC5474459

  13. Okusaga, O, Fuchs, D, Reeves G, Giegling I, Hartmann AM, Konte B, Friedl M, Groer M, Stearns-Yoder KA, Pandey JP, Kelly DL, Hoisington AJ, Lowry CA, Eaton WW, Brenner LA, Rujescu D, Postolache TT.  Kynurenine and trypophan levels in patients with schizophrenia and elevated anti-gliadin immunoglobulin G antibodies.  Psychosomatic Medicine.  2016;78:931-939. PMID: 27359171 PMCID: PMC5338470

  14. Eaton WW, Chen LY, Dohan FC Jr. Kelly DL, Cascella N. Improvement in psychotic symptoms after a gluten-free diet in a boy with complex autoimmune illness. Am J Psychiatry 2015;172:219-21. PMID: 25727533 PMCID: PMC4477691

  15. Jackson J, Eaton W, Cascella N, Fasano A, Santora D, Sullivan K, Feldman S, Raley H, McMahon RP, Carpenter WT Jr, Demyanovich H, Kelly DL. Gluten Sensitivity and relationship to psychiatric symptoms in people with schizophrenia. Schizophr Res 2014;159:539-42. PMID: 25311778 PMCID: PMC4476307 

  16. Okusaga O, Yolken RH, Langenberg P, Sleemi A, Kelly DL, Vaswani D, Giegling I, Hartmann AM, Konte B, Friedl M, Mohyuddin F, Groer MW, Rujescu D, Postolache TT. Elevated gliadin antibody levels in individuals with schizophrenia. World J Biol Psychiatry 2013;14:509-15. PMID: 23282016.

  17. Warren KR, Buchanan RW, Feldman S, Conley RR, Linthicum J, Ball MP, Liu F, McMahon RP, Gorelick DA, Huestis MA, Kelly DL. Effects of the cannabinoid-1 receptor antagonist/inverse agonist rimonabant on satiety signaling in overweight people with schizophrenia: a randomized, double-blind pilot study. J Clin Psychopharmacol 2013;33:118-20.  PMID:  23277241 PMCID: PMC3836264

  18. Jackson J, Eaton W, Cascella N, Fasano A, Kelly DL.  Neurologic and Psychiatric Manifestations of Celiac Disease and Gluten Sensitivity.  Psychiatric Quarterly.  2012;83:91-102.  PMID: 21877216 PMCID: PMC3641836

  19. Jackson J, Eaton W, Cascella N, Fasano A, Warfel D, Feldman D, Richardson C, Vyas G, Linthicum J, Santora D, Warren KR, Carpenter WT, Jr, Kelly DL. A gluten free diet in people with schizophrenia and anti-tissue transglutaminase or anti-gliadin antibodies. Schizophr Res 2012;140:262-3. PMID: 22771303 PMCID: PMC3641835

  20. Kelly DL, Gorelick DA, McMahon RP, Boggs DL, Linthicum J, Liu F, Feldman S, Ball MP, Richardson CM, Conley RR, Gold JM, Wehring HJ, Kearns AM, Huestis MA, Buchanan RW. Effects of the Cannabinoid-1 Receptor Antagonist Rimonabant on Psychiatric Symptoms In Overweight People with Schizophrenia: A Randomized, Double-Blind Pilot Study, J Clinical Psychopharmacology, 2011;31:86-91 PMID: 21192149 PMCID: PMC3717343

  21. Cascella NG, Kryszak D, Bhatti B, Gregory P, Kelly DL, McEvoy JP, Fasano A, Eaton WW. Prevalence of celiac disease and gluten sensitivity in the United States Clinical Antipsychotic Trials of Intervention Effectiveness Study Population. Schizophr Bull. 2011;37:94-100, PMID:19494248 PMCID: PMC3004201

  22. Ball MP, Warren KR, Feldman S, McMahon RP, Kelly DL, Buchanan RW: Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine. Clin Schizophr Relat Psychoses. 2011. Apr;5(1):17-25. PMID: 21459735

  23. Wehring HJ, Liu F, McMahon RP, Spieker EA, Warren KR, Boggs DL, Love RC, Dickinson D, Shim JC, Fowler D, Kelly DL. The relationship of brain weight to body mass index (BMI) upon autopsy in young people with severe mental illness. Schizophrenia Research. 2010;123:86-7.  

  24. Kelly DL, Conley RR, Love RC, Morrison JA, McMahon RP. Metabolic Risk With Second-Generation Antipsychotic Treatment: A Double-Blind Randomized 8-week Trial of Risperidone and Olanzapine. Annals of Clinical Psychiatry. 2008;20:71-8. PMID:18568578

  25. Conley RR, Shim JC, Kelly DL, Yu Y, Feldman S, McMahon RP. Cardiovascular disease in Relation to Weight in deceased persons with schizophrenia. Comprehensive Psychiatry. 2005;46:460-7. PMID:16275214

  26. Kelly DL, Kreyenbuhl J, Love RC, Van-Duong Q, Conley RR. Six-month review of weight and metabolic parameters in patients on clozapine, risperidone, olanzapine and quetiapine. Journal of Clinical Psychiatry. 2003;64:1133-4. PMID: 14628994.

  27. Kelly DL, Conley RR, Richardson CM, Tamminga CA, Carpenter WT Jr. Adverse Effects and Laboratory Parameters of High-Dose Olanzapine vs. Clozapine in Treatment-Resistant Schizophrenia. Annals of Clin Psychiatry. 2003;15:181-6. PMID: 14971863.

  28. Kelly DL, Conley RR, Love RC, Horn DS, Ushchak CM.  Weight gain in adolescents treated with risperidone and conventional antipsychotics. The Journal of the Child and Adolescent Psychopharmacology. 1998;8:151-159. PMID: 9853689.